<DOC>
	<DOCNO>NCT00524459</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , liposomal doxorubicin docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) give surgery may kill tumor cell . PURPOSE : This phase II trial study side effect give liposomal doxorubicin together docetaxel surgery see well work treat woman locally advance breast cancer remove surgery .</brief_summary>
	<brief_title>Pegylated Liposomal Doxorubicin Docetaxel Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate rate pathological complete response clinical complete response woman locally advance breast cancer treat pegylated doxorubicin hydrochloride liposome docetaxel . Secondary - To assess overall clinical local regional response patient treat preoperative chemotherapy regimen . - To evaluate number patient would require mastectomy upfront underwent breast conservation therapy instead neoadjuvant chemotherapy . - To assess safety , particularly regard neutropenia cardiac toxicity , pegylated doxorubicin hydrochloride liposome docetaxel . OUTLINE : This multicenter study . Patients receive pegylated doxorubicin hydrochloride liposome IV 90 minute docetaxel IV 90 minute day 1 . Patients receive pegylated filgrastim subcutaneously day 2 3 post-chemotherapy course 1-5 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Within 8 week completion chemotherapy , patient undergo lumpectomy mastectomy remove tumor . Some patient may receive additional therapy surgery , include hormonal therapy , chemotherapy , radiotherapy . After completion study therapy , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm breast cancer use core biopsy Locally advance disease Resectable disease Fine needle aspiration cytology allow must demonstrate invasive adenocarcinoma No 8 week since initial cytologic histologic diagnosis breast cancer Tumor must meet following criterion : Palpable clinical examination confine either breast breast ipsilateral axilla Measured clinically great 2 cm size ( T2 ) Patients skeletal pain eligible bone scan and/or roentgenological examination fail disclose metastatic disease Suspicious finding must confirm benign xray , MRI scan , biopsy Hormonal status specify PATIENT CHARACTERISTICS : Inclusion criterion : Female Menopausal status specify ECOG performance status 02 Life expectancy ≥ 10 year Platelet count ≥ 100,000/mm³ ANC ≥ 1,500/mm³ Hemoglobin ≥ 9.0 g/dL Bilirubin normal AST ALT normal Alkaline phosphatase normal Serum creatinine normal Negative pregnancy test Fertile patient must use effective contraception ( e.g. , abstinence , intrauterine device , barrier device spermicide , surgical sterilization ) 3 month completion study therapy Normal cardiac function LVEF MUGA scan Patients prior nonbreast malignancy eligible diseasefree ≥ 10 year The following allow even diagnose within past 10 year : Squamous basal cell carcinoma skin effectively treat Carcinoma situ cervix treat operation Lobular carcinoma situ ipsilateral contralateral breast treat segmental resection Exclusion criterion : Pregnant lactate woman Male patient Hyperbilirubinemia Female patient 1 follow condition : Ulceration , erythema , infiltration skin ( complete fixation ) , peau d'orange ( edema ) magnitude Tethering dimple skin nipple inversion interpret skin infiltration Ipsilateral lymph node clinically fix one another structure ( N2 disease ) Bilateral malignancy mass opposite breast suspicious malignancy , unless biopsy proof mass malignant Suspicious palpable node contralateral axilla palpable supraclavicular infraclavicular node , unless biopsy evidence involve tumor Nonmalignant systemic disease ( e.g. , cardiovascular , renal , hepatic ) would preclude study therapy Active cardiac disease would preclude use doxorubicin hydrochloride , include follow : Documented myocardial infarction Angina pectoris require use antianginal medication History document New York Heart Association class IIIV heart failure Valvular disease document cardiac function compromise Poorly control hypertension ( i.e. , diastolic BP &gt; 100 mm Hg ) Patients wellcontrolled hypertension medication eligible study Psychiatric addictive disorder would preclude obtain informed consent PRIOR CONCURRENT THERAPY : Inclusion criterion : Concurrent noncancer therapy allow used condition breast cancer Adjuvant therapy surgery allow Exclusion criterion : Prior radiotherapy , chemotherapy , immunotherapy , and/or hormonal therapy breast cancer Prior anthracycline therapy condition Concurrent hormonal therapy include tamoxifen , aromatase inhibitor , raloxifene Concurrent sex hormonal therapy include birthcontrol pill ovarian hormonal replacement therapy Concurrent cancer therapy Concurrent herbal alternative therapy breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>